106 results about "Prurigo" patented technology

The invention relates to dermatological compositions of Oxaprozin or a closely related compound suitable adapted for the treatment of a dermatological disease, where at least two of the enzymes selected from protein tyrosine kinase Syk, protein tyrosine kinase ZAP-70 and phosphodiesterase IV play a role in mediating the dermatological disease. The invention also encompasses dermatological compositions for the treatment of pruritus.

A condensed pyridazine derivative which is useful as a pharmaceutical composition for preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria and prurigo.

A composition containing capsaicin together with other ingredients to neutralize the discomfort resulting from the application of capsaicin to the ski enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post surgical scarring, hemorrhoid pain and itching, and pruritis without the discomfort normally associated with the topical application of capsaicin.

The invention aims to find out a novel pharmacological effect (medical use) of cannabinoid. Since cannabinoid agonists such as palmidrol and anandamide have an excellent antipruritic effect, they are useful as an agent for treating any types of pruritus such as ocular pruritus, skin pruritus and systemic pruritus.

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba / F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

External preparations for treating pruritus containing Aspirin as an active ingredient, which exert an excellent therapeutic effects on pruritus with less side effects.

The present invention provides a method and composition for treating pruritus, and also psoriasis which includes applying a compound of formula (I) in a suitable formulation to the affected area. Compounds of formula (I) can also be formulated as a vaginal cream to inhibit viruses such as HIV, and possibly prevent the transmission of other sexually transmitted diseases.

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba / F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

The invention provides a honeysuckle flower cellulose fiber. The honeysuckle flower cellulose fiber is prepared from flax pulp; the honeysuckle flower cellulose fiber contains 5% or more of honeysuckle flower extract, 1-3% of pine bark extract and 2-6% of proteins; the dry fracture strength of the honeysuckle flower cellulose fiber is 3.6-4.2 cN / dtex; the wet fracture strength is 2.3-2.8 cN / dtex; and the dry elongation at break is 21.6-22.5%. The honeysuckle flower cellulose fiber prepared in the invention adopts the flax pulp as a raw material, and the flax contains unsaturated fatty acids, so the honeysuckle flower cellulose fiber has good repairing and protecting effects on skins, has no irritation, has the efficacy of moisturizing dryness, detoxifying, relieving pains and eliminating swelling, and can be used for preventing and treating prurigo and allergy of skins; and a fabric made of the honeysuckle flower cellulose fiber has good compatibility with skins.

The invention relates to a medical soap for treating pruritus, which is prepared from Schizonepeta tenuifolia, ledebouriella root, fresh ginger, notopterygium root, pubescent angelica root, Bupleurum root, peppermint leaves, peucedanum root, root of ballon flower, licorice root, bitter orange, poria cocos, Chinese angelica root, Ligusticum wallichii and root of herbaceous peony.

The present invention encompasses methods and combinations for substantially inhibiting the opioid-induced internalization of GRPR in a pruritis specific neuron. Such methods and combinations provide a direct means of treating opioid-induce pruritis without compromising opioid analgesia.

The invention discloses a potentilla plant extract which includes not less than 6% w / w of procyanidine B7 and not less than 4% w / w of 2,3,4,6-tetra-O-galloylglucose. The extract is used for resisting inflammation and oxidization, promoting wound healing, resisting bacteria and virus, promoting urine, eliminating edema, treating dermatophytosis due to cold and dampness and treating prurigo and mastitis. In the invention, four tannin compounds, including procyanidine B3, procyanidine B6, the procyanidine B7 and the 2,3,4,6-tetra-O-galloylglucose, are separated and prepared from the potentilla plant extract, product purities being higher than 95%. The method has large preparation quantity and is suitable for industrial application.

The present invention is based on the discovery that a nalmefene salt or a peripherally acting analogue of nalmefene is capable of providing long-acting activity against pruritus, when applied topically. In addition, treatment with a nalmefene salt or peripherally acting analogue of nalmefene, can provide disease-modifying effects against the chronic symptoms of atopic dermatitis, including reductions of inflammatory cell infiltrate into the skin, epidermal hyperplasia and trans-epidermal water loss. Compositions of the invention have an inhibitory effect on the itch-scratch-cycle, leading to both relief of pruritus and disease-modifying activity.

The present invention comprises a method of treating pediatric patients suffering from an inflammatory or pruritic skin disorder comprising topically applying fluocinonide to an affected area. Treatment according to this method does not result in clinically significant suppression of the HPA-axis.

The invention provides an externally used pharmaceutical composition for treating eruption. The externally used pharmaceutical composition is an externally used preparation prepared by the following active ingredients in parts by weight: 14-26 parts of fructus kochiae, 14-26 parts of fructus cnidii, 14-26 parts of chaulmoogra tree seeds, 14-26 parts of radix sophorae flavescentis, 14-26 parts of smilax glabra, 14-26 parts of cortex dictamni, 8-16 parts of radix lithospermi, and 8-16 parts of herba schizonepetae. The invention further provides a preparation method and applications for the pharmaceutical composition. The pharmaceutical composition can effectively eliminate or greatly relieve the symptoms of eruption diseases such as eczema, prurigo and the like, can eliminate disease source influence of hypersensitivity and the like and heal the primary diseases, and provides a new choice for clinical medicine.

The invention provides a medicine composition for treating rashes. The medicine composition is a preparation prepared from the following active pharmaceutical ingredients in parts by weight: 20-40 parts of lemna minor, 17-31 parts of coix seed, 17-31 parts of rhizoma smilacis glabrae, 10-20 parts of belvedere fruit, 7-13 parts of radix sophorae flavescentis, 7-13 parts of cortex dictamni, 7-13 parts of rhizoma atractylodes, 17-31 parts of flaxseed, 7-13 parts of periostracum cicadae, 2-5 parts of Chinese tamarisk twig, 4-8 parts of fineleaf schizonepeta herb, 4-8 parts of divaricate saposhnikovia root, 5-11 parts of great burdock achene, 17-31 parts of gypsum, 7-13 parts of rhizoma anemarrhenae, 7-13 parts of cortex phellodendri, 10-20 parts of Sinkiang arnebia root, 8-16 parts of radix rehmanniae, 7-13 parts of angelica sinensis and 2-5 parts of liquorice. The invention also provides a preparation method and an application of the medicine composition. The medicine composition can effectively eliminate or greatly relieve the symptoms of such rash diseases as eczema, prurigo and rubella, can cure the primary diseases to some extent and provides a new choice for clinical medication.

The present invention relates to a health food or pharmaceutical composition for alleviating or suppressing pruritus, comprising chestnut shell extract as an active ingredient. In one example of the present invention, the chestnut shell extract comprised in the health food or pharmaceutical composition of the present invention can suitably be used as the active ingredient of a health food or pharmaceutical composition for alleviating or suppressing pruritus as it has been confirmed that it can exhibit an outstanding effect in alleviating or suppressing pruritus by suppressing the activity of proteinase-activated receptor-2 (PAR-2) which is a source of stimulation in pruritus.

The invention relates to a traditional Chinese medicine composition for treating prurigo. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials according to weight ratios: 5-25 g of angelica, 5-25 g of red peony root, 5-25 g of hemlock parsley, 10-40 g of dried rehmannia root, 5-25 g of cortex moutan, 10-30 g of figwirt root, 5-20 g of cicada skin, 5-25 g of motherwort fruit, 5-25 g of cynanchum paniculatum, 5-20 g of snake slough, 5-25 g of root-bark of ditlany, 5-25 g of tribulus terrestris, 5-25 g of flavescent sophora root, 5-20 g of nepeta, 5-20 g of ledebouriella root, 5-20 g of peach kernel and 5-20 g of safflower. The traditional Chinese medicine composition provided by the invention has the effects of clearing away heat and expelling wind, promoting qi circulation and eliminating stasis, detoxifying toxicity and relieving itching as well as activating blood and channels, and has the advantages of significant treatment effect on prurigo, reliable action, wide component medicine sources, simple preparation, low cost, mild drug properties and no toxic or side effect.

The invention discloses a tincture and a preparation method thereof for treating prurigo nodularis, which is made of the following materials by weight proportions: 30-10 portions of cortex dictamni, 30-10 portions of khosam, 30-10 portions of selinum, 30-10 portions of broom cypress fruit, 30-10 portions of gallnut, 30-10 portions of red paeonia, 30-10 portions of trigone, 30-10 portions of rhizoma zedoariae, 30-10 portions of white caltrop, 30-10 portions of parsnip, 1200-400 portions of 75 percent alcohol. The preparation method is to soak the cortex dictamni, the khosam, the selinum, the broom cypress fruit, the gallnut, the red paeonia, the trigone, the rhizoma zedoariae, the white caltrop, and the parsnip in the 75 percent alcohol for ten days, and then to filter the medicine dregs; the obtained filtrate is the tincture for treating prurigo nodularis. The tincture has the beneficial effects that the tincture is pure herbal external tincture, can reduce damp fever, remove cold and stop itch, withdraw acerbity and dispel tubercle; can cure the prurigo nodularis effectively without side effect, and can be used conveniently.

The invention relates to the technical field of Chinese medicines, in particular to a medicinal composition for preventing and treating skin eczema and skin pruritus, a formulation and application. The medicinal composition comprises the following substances in part by weight: 5 to 30 parts of glycyrrhizin, 5 to 30 parts of baical skullcap root extract, 5 to 30 parts of propolis extract and 10 to 100 parts of hemp seed oil. The medicinal composition comprises a Chinese medicinal composition and a pharmaceutically acceptable carrier; and the formulation is an emulsion, cream, a tincture, distillate medicinal water, a liniment, a lotion, a film coating agent or a spray. The invention also relates to the application of the medicinal composition and the formulation to the preparation of a medicine for preventing and treating the skin eczema and the skin pruritus. The invention has the advantages that: the preparation process is simple, and the medicine has uniform and stable quality; and the medicinal composition can effectively prevent and treat the skin eczema and the skin pruritus, has the effect of inhibiting and / or killing various bacteria and viruses, and has good effects of maintaining skin moisture and moistening at the same time.

The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating acute or chronic pruritus associated with a variety of medical conditions, including dermatitis / eczema, psoriasis, prurigo, urticaria, cutaneous T-cell lymphoma, epidermolysis bullosa, bums and hepato-biliary diseases, or / and treating the medical conditions themselves. One or more additional antipruritic or therapeutic agents can optionally be used in combination with an NK-1 antagonist to treat acute or chronic pruritus associated with a medical condition or / and the medical condition itself.

The invention discloses skin physiology repair liquid and a preparation method thereof. The skin physiology repair liquid is prepared by confecting and concentrating composite chitosan solution, gelatin, glycerin and Chinese herb extraction liquid; wherein, the composite chitosan solution is prepared by concentrating chitosan, water soluble low-molecular weight chitosan, chitosan hydrochloride and carboxymethyl chitosan, which are dissolved in diluted citric acid; the Chinese herb extraction liquid is extracted from coptis chinensis, fructus cnidii, radix scutellariae, rosemary, lightyellow sophora root, sophora alopecuroides, mulberry leaf, snow lotus and propolis. The invention achieves the effective rate of 89% in the first course of treatment of blain spots, cutaneous pruritus, contact dermatitis, allergic prurigo and spots and the effective rate of 95% in the second course of treatment. Antibacterial effects on gonococcus, staphylococcus aureus, colon bacillus and white cocci in laboratories excel the antibacterial effects of the commonly-used product Jieeryin lotion. The skin physiology repair liquid achieves the cure rate of 95% in the first course of treatment of gynecological leucorrhoea peculiar smell, vagina pruritus, congestion of vagina mucosa and vulva peculiar smell and the cure rate of 100% in the second course of treatment.

The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.

A method for treating pruritus by topically applying a composition comprising a hedgehog inhibitor compound is provided.

Disclosed are topical formulations comprising an androstane steroid, propylene glycol, and benzyl alcohol in an amount effective to dissolve the androstane steroid compound, wherein the amount of benzyl alcohol is not effective to act as a penetration enhancer. The formulations are useful for the treatment of inflammatory and / or pruritic manifestations of corticosteroid-responsive dermatoses.